Peptides and Complex Regional Pain Syndrome (CRPS)

By the NorthPeptide Research Team — Updated January 2026

Understanding CRPS

Complex Regional Pain Syndrome is divided into two types: CRPS Type I (no confirmed nerve injury) and CRPS Type II (confirmed nerve injury). Both feature pain, swelling, skin changes, and motor dysfunction that far exceed what the initial injury would predict. The condition is thought to involve central and peripheral sensitization, neurogenic inflammation, sympathetic nervous system dysfunction, and immune dysregulation. It affects roughly 200,000 people in the United States annually and can be severely disabling.

Conventional treatments include physical therapy, sympathetic nerve blocks, ketamine infusions, and spinal cord stimulation — with highly variable outcomes. This therapeutic gap has motivated research into peptide compounds that act on inflammation, nerve repair, and vascular function.

Why Peptides Are Studied for CRPS

The multisystem nature of CRPS — involving nerves, blood vessels, immune cells, and the central nervous system — makes it a candidate for interventions that act across several pathways simultaneously. This is a defining characteristic of several research peptides. Rather than blocking a single receptor, compounds like BPC-157 appear to modulate multiple regulatory systems at once.

BPC-157 in CRPS-Relevant Research

BPC-157 has been studied in numerous animal models that replicate aspects of CRPS pathology:

• Neurogenic inflammation: BPC-157 has demonstrated ability to counter the release of substance P and calcitonin gene-related peptide (CGRP) — key mediators of neurogenic inflammation
• Vascular normalization: CRPS features abnormal blood flow patterns; BPC-157 promotes angiogenesis and nitric oxide regulation, which may help restore vascular tone
• Sympathetic modulation: Some animal research suggests BPC-157 interacts with the dopaminergic system, which has cross-talk with sympathetic pain pathways
• Mechanical allodynia reduction: Rat models of neuropathic pain treated with BPC-157 showed significant reductions in allodynia markers

TB-500 and Connective Tissue Involvement in CRPS

TB-500 (Thymosin Beta-4) is a naturally occurring peptide involved in cell migration, wound healing, and anti-inflammatory signaling. In the context of CRPS, its relevance stems from:

• Reduction of inflammatory cytokine production (IL-1β, TNF-α) in injury models
• Support for muscle and connective tissue repair, which may aid the physical rehabilitation component of CRPS treatment
• Potential effects on fibrosis — chronic CRPS can result in tissue thickening and contracture

Animal studies have shown TB-500 to reduce inflammatory pain signaling in collagen-induced arthritis models, offering a loose but suggestive parallel to some CRPS features.

Gaps in the Research

It is critical for researchers to understand what is not yet known:

• No human clinical trials for BPC-157 or TB-500 in CRPS patients have been published
• CRPS animal models are imperfect — most use chronic constriction injury, which approximates Type II but not Type I
• The role of the immune system in CRPS is still not fully characterized, making it hard to predict which peptide mechanisms would be most relevant
• Dosing in animals does not translate directly to human equivalents

Research Products

NorthPeptide supplies research-grade peptides for laboratory investigation into pain, inflammation, and nerve repair mechanisms.

Related Research Articles

PubMed Citations